Pioneer Trust Bank N A OR Acquires 2,926 Shares of Pfizer Inc. (NYSE:PFE)

Pioneer Trust Bank N A OR boosted its stake in Pfizer Inc. (NYSE:PFE) by 30.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 12,560 shares of the biopharmaceutical company’s stock after buying an additional 2,926 shares during the period. Pioneer Trust Bank N A OR’s holdings in Pfizer were worth $333,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Retirement Wealth Solutions LLC bought a new position in shares of Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the fourth quarter worth $32,000. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 5.4 %

NYSE PFE opened at $22.99 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $130.39 billion, a P/E ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.61. The business has a fifty day simple moving average of $25.87 and a 200 day simple moving average of $26.76. Pfizer Inc. has a 12 month low of $22.95 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% on a year-over-year basis. During the same period last year, the firm earned $0.10 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Citigroup reiterated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.